Study finds incidence of type 2 diabetes reduced by 32% in participants taking dapagliflozin vs. placebo.
Read More »Association Between T1D, Hypoglycemia, and BMI
Type 1 diabetes mellitus patients with high BMI and hypoglycemia may improve quality of life through dapagliflozin treatment.
Read More »Benefits of GLP1 RA and SGLT-2 Inhibitors in Type 2 Patients
GLP1 RA and SGLT-2 were compared to evaluate coronary health disease reduction in patients with type 2 diabetes.
Read More »How to Eliminate Carb Counting for Type 1 Pump Users
Could adding a SGLT-2 inhibitor to a closed-loop automated insulin delivery reduce the need for carbohydrate counting?
Read More »Treating Kidney Disease With Dapagliflozin
Researchers discovered that dapagliflozin helped patients with and without diabetes in improving kidney disease.
Read More »Canagliflozin Effects on Heart Failure and Cardiovascular Death
Canaglifozin reduced risk of cardiovascular death and hospitalizations due to heart failure by 31%.
Read More »Canagliflozin Linked to Improved Anemia in Patients with Diabetes and Renal Disease
SGLT-2 inhibitors show additional benefits besides lowering blood glucose.
Read More »Impact of Sotagliflozin Added to Insulin
What is the impact of adjunctive sotagliflozin to insulin therapy on diabetes distress and treatment satisfaction in patients with type 1 diabetes?
Read More »Left Ventricular Mass Reduction and Empagliflozin
Empagliflozin significantly lowered LVMi, systolic blood pressure, and diastolic blood pressure in patients with CAD and type 2 diabetes.
Read More »Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.